Qiagen N.V. launched two novel liquid biopsy panels to evaluate circulating tumor cells (CTCs) in the growing field of research into molecular mechanisms in prostate and lung cancers. The AdnaTest ProstateCancerPanel AR-V7 Kit and AdnaTest LungCancer Kit will be introduced at the American Association for Cancer Research (AACR) 2018 Annual Meeting from April 14-18 in Chicago. The new AdnaTests build on Qiagen’s proprietary AdnaTest Combination of Combinations Principle technology, a highly specific immunomagnetic cell-selection system for enriching circulating tumor cells (CTCs) from peripheral blood that allows sensitive analysis of cancer-associated gene expression.

The novel AdnaTest ProstateCancerPanel AR-V7 Kit provides new insights into tumor biology by detecting the androgen receptor splice variant 7 in CTCs of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. With an exclusive worldwide license from Johns Hopkins University for nucleic acid detection of the AR-V7 biomarker for diagnostic use, Qiagen is now launching the test for research use. Johns Hopkins researchers first highlighted the potential clinical relevance of AR-V7 in a 2014 article in the New England Journal of Medicine.

The new AdnaTest LungCancer Kit delivers unique insights into the molecular mechanisms of lung cancer through highly specific selection of CTCs, including stem cell-like cells implicated in cancer growth and epithelial-mesenchymaltransition (EMT), an important marker of resistance to cancer therapy. A proprietary set of antibodies provides sensitive detection of lung cancer-associated targets through reverse-transcriptase PCR. The open system ensures flexibility for users to add the targets of interest.

We are excited to collaborate with the cancer research community at AACR 2018 in driving innovative science to fulfil the hope of improving patient care. Our AdnaTest liquid biopsy-based portfolio now offers molecular characterization in leading cancers with insights into tumor biology, pathways, relevant biomarkers, cancer progression, and even resistance to therapy, said Dr Thomas Schweins, senior vice president and head of Qiagen’s Life Sciences Business Area. – Medical Buyer Bureau

10 Diagnostic Imaging Trends for 2018



Digital version